Post-Traumatic Stress Disorder Medication Prescribing Improvement Act of 2016

Bill: 114-s-2861
Sponsor: full_name: Sen. Rounds, Mike [R-SD]
Introduced: 2016-04-27
Policy area: Armed Forces and National Security
Subjects: Drug therapy

Government studies and investigations

Military medicine

Neurological disorders

Prescription drugs
Latest action: action_date: 2016-04-27
text: Read twice and referred to the Committee on Armed Services.

Summaries:
action_date: 2016-04-27
action_desc: Introduced in Senate
text: <p><strong>Post-Traumatic Stress Disorder Medication Prescribing Improvement Act of 2016</strong></p> <p>This bill directs the Department of Defense to: (1) review the prescribing practices at military treatment facilities of pharmaceutical agents for post-traumatic stress treatment, (2) implement a process or processes to monitor the prescribing practices at military treatment facilities of pharmaceutical agents that are discouraged from use under the VA/DOD Clinical Practice Guideline for Management of Post-Traumatic Stress, and (3) implement a plan to address deviations from such guideline. </p>

tv_txt: II 114th CONGRESS 2d Session S. 2861 IN THE SENATE OF THE UNITED STATES April 27, 2016 Mr. Rounds introduced the following bill; which was read twice and referred to the Committee on Armed Services A BILL To require the Secretary of Defense to review and monitor prescribing practices at military treatment facilities of pharmaceutical agents for the treatment of post-traumatic stress.

1. Short title This Act may be cited as the Post-Traumatic Stress Disorder Medication Prescribing Improvement Act of 2016 . 2. Requirement to review and monitor prescribing practices at military treatment facilities of pharmaceutical agents for treatment of post-traumatic stress (a) In general Not later than 180 days after the date of the enactment of this Act, the Secretary of Defense shall— (1) conduct a comprehensive review of the prescribing practices at military treatment facilities of pharmaceutical agents for the treatment of post-traumatic stress; (2) implement a process or processes to monitor the prescribing practices at military treatment facilities of pharmaceutical agents that are discouraged from use under the VA/DOD Clinical Practice Guideline for Management of Post-Traumatic Stress; and (3) implement a plan to address any deviations from such guideline in prescribing practices of pharmaceutical agents for management of post-traumatic stress at such facilities. (b) Pharmaceutical agent defined In this section, the term pharmaceutical agent has the meaning given that term in section 1074g(g) of title 10, United States Code.